Elicera Therapeutics AB (publ) (STO:ELIC)
2.480
0.00 (0.00%)
Jun 11, 2026, 5:29 PM CET
Elicera Therapeutics AB Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 17.86 | 24.85 | 26.4 | 29.38 | 43.82 | 52.39 |
Cash & Short-Term Investments | 17.86 | 24.85 | 26.4 | 29.38 | 43.82 | 52.39 |
Cash Growth | -60.87% | -5.88% | -10.15% | -32.95% | -16.36% | 353.04% |
Other Receivables | 3.04 | 0.05 | 0.88 | 0.34 | 0.33 | 0.2 |
Receivables | 3.04 | 0.05 | 0.88 | 0.34 | 0.33 | 0.2 |
Prepaid Expenses | - | 2.03 | 0.28 | 0.45 | 1.65 | 1.62 |
Other Current Assets | - | - | - | - | -0 | -0.01 |
Total Current Assets | 20.9 | 26.93 | 27.57 | 30.17 | 45.8 | 54.21 |
Long-Term Investments | - | - | 0 | 0 | 0.48 | 0.48 |
Other Intangible Assets | - | - | - | 0.01 | 0.02 | 0.04 |
Other Long-Term Assets | - | 0.49 | - | - | -0 | 0.01 |
Total Assets | 20.9 | 27.42 | 27.57 | 30.18 | 46.31 | 54.74 |
Accounts Payable | 0.85 | 2.57 | 2.04 | 0.88 | 0.73 | 2.05 |
Accrued Expenses | 1.48 | 1.24 | 4.4 | 12.5 | 12.53 | 0.31 |
Current Income Taxes Payable | - | - | - | - | 0.01 | 0 |
Other Current Liabilities | 0.27 | 0.25 | 0.35 | 0.4 | 0.24 | 0.14 |
Total Current Liabilities | 2.6 | 4.06 | 6.8 | 13.78 | 13.51 | 2.5 |
Total Liabilities | 2.6 | 4.06 | 6.8 | 13.78 | 13.51 | 2.5 |
Common Stock | 2.04 | 2.04 | 1.47 | 0.83 | 0.83 | 0.83 |
Additional Paid-In Capital | 21.32 | 106.06 | 86.62 | 66.79 | 66.79 | 66.79 |
Retained Earnings | -5.06 | -84.73 | -67.33 | -51.22 | -34.82 | -15.38 |
Comprehensive Income & Other | - | - | - | - | -0 | -0 |
Shareholders' Equity | 18.3 | 23.36 | 20.77 | 16.4 | 32.8 | 52.24 |
Total Liabilities & Equity | 20.9 | 27.42 | 27.57 | 30.18 | 46.31 | 54.74 |
Net Cash (Debt) | 17.86 | 24.85 | 26.4 | 29.38 | 43.82 | 52.39 |
Net Cash Growth | -60.87% | -5.88% | -10.15% | -32.95% | -16.36% | 353.04% |
Net Cash Per Share | 0.37 | 0.54 | 0.84 | 1.49 | 2.21 | 3.27 |
Filing Date Shares Outstanding | 48.54 | 48.54 | 35.09 | 19.78 | 19.78 | 19.78 |
Total Common Shares Outstanding | 48.54 | 48.54 | 35.09 | 19.78 | 19.78 | 19.78 |
Working Capital | 18.3 | 22.87 | 20.77 | 16.39 | 32.29 | 51.71 |
Book Value Per Share | 0.38 | 0.48 | 0.59 | 0.83 | 1.66 | 2.64 |
Tangible Book Value | 18.3 | 23.36 | 20.77 | 16.39 | 32.78 | 52.2 |
Tangible Book Value Per Share | 0.38 | 0.48 | 0.59 | 0.83 | 1.66 | 2.64 |